HS-10296 hydrochloride

Almonertinib (HS-10296) hydrochloride is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib hydrochloride shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC50: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Almonertinib hydrochloride is used for the research of the non-small cell lung cancer[1][2].


Cat. No.: EX-A3721A	Purity: >98%

	Chemical structure of HS-10296 hydrochloride

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
250mg	502	in_stock
500mg	795	in_stock
1g	1295	in_stock
2g	2000	in_stock
3g	2494	in_stock
5g	3315	in_stock

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


CAS No.	2134096-03-8
Purity	>98%
Formula	C30H36ClN7O2
Mol Weight	562.106
Color	Off-white to yellow
State	Solid
Solubility	soluble in DMSO/H2O
Shelf Life	>3 years if stored properly
Storage	Powder 4°C, sealed storage, away from moisture; In solvent -20°C, 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Sullivan I, et al. Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line. Front Med (Lausanne). 2017 Jan 18;3:76. [2]. Wu SG, et al. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018 Feb 19;17(1):38. [3]. Yang JC, et al. Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial [published online ahead of print, 2020 Sep 9]. J Thorac Oncol. 2020;S1556-0
CoA	CoA of HS-10296 hydrochloride

Smiles:	COC(C=C(N(C)CCN(C)C)C(NC(C=C)=O)=C1)=C1NC2=NC(C3=CN(C4CC4)C5=C3C=CC=C5)=CC=N2.[H]Cl


		Search